Eli Lilly and Company (BMV:LLY)

Market Cap	13.30T
Revenue (ttm)	1.00T
Net Income (ttm)	227.00B
Shares Out	n/a
EPS (ttm)	251.19
PE Ratio	58.60
Forward PE	30.10
Dividend	111.06 (0.75%)
Ex-Dividend Date	May 16, 2025

Volume	4
Average Volume	2,031
Open	14,689
Previous Close	14,319
Day's Range	14,689 - 14,788
52-Week Range	12,809 - 19,261
Beta	0.47
RSI	42.89
Earnings Date	May 1, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD